{
  "id": "cluster_47_doc2",
  "content": "Alderwood Neurosciences quarterly report notes 12% increase in neuromodulation procedures following recent FDA approval. Noteworthy case: G. Wildermuth (DOB 8/15/1978) with refractory neuropathic pain from lumbar disc degeneration responded exceptionally to trial therapy. Research team secured insurance coverage exception after multiple appeals.",
  "metadata": {
    "format": "research_note"
  }
}